One maturity label cannot carry six claims
A prototype may be technically stable while its scientific premise remains uncertain. A validated prediction may be unusable in workflow. A product may integrate cleanly while creating inequitable access or an unacceptable failure mode. Teams often compress these dimensions into “pilot ready” or a single readiness number, allowing strength in one area to mask weakness in another. Translation needs a vector of claims: scientific validity, measurement validity, system performance, human and operational fit, governance readiness, and outcome evidence.
NASA’s nine Technology Readiness Levels are valuable because they anchor maturity to evidence in an environment, from observed principles to flight-proven operation. NASA also notes that context matters and that a technology is assessed against parameters for each level. Borrowing the scale outside aerospace should preserve that discipline rather than rename a slide. A laboratory should define the intended operational environment and objective exit evidence for every maturity dimension.
Start with a claim–evidence matrix
Every proposed capability should be decomposed into claims that could be false. “Detects deterioration” becomes a target population, prediction horizon, reference outcome, input availability, acceptable calibration, alert threshold, and clinical response. “Reduces cost” becomes a perspective, resource categories, time horizon, comparator, and uncertainty analysis. The matrix links each claim to evidence, source, maturity, owner, unresolved threat, and next decisive test. Unsupported claims remain visible rather than disappearing into narrative.
The comparison condition must be measured with equal seriousness. Current practice may be slow but resilient, or inconsistent but capable of handling exceptions. A new system can move labor from one team to another, increase downstream testing, or create a new dependency while shortening one task. Baseline time, error, workload, cost, and outcome distributions let evaluators identify net change. Without them, deployment becomes a before-free demonstration in which every activity appears additive.
Verification and validation answer different questions
Verification asks whether the system was built according to specification. Validation asks whether it meets its intended use in context. Components, interfaces, data, models, and complete workflows each need appropriate tests. Unit and integration testing cannot establish human benefit; a successful user study cannot compensate for unbounded data corruption. Test evidence should include configuration, environment, version, sample, protocol, expected result, observed result, deviations, and reviewer.
For software as a medical device, the IMDRF clinical-evaluation framework separates valid clinical association, analytical validation, and clinical validation. The pattern generalizes: establish that the phenomenon relates to the target condition, that the system processes inputs accurately and reliably, and that the output achieves its intended purpose in the target population. These questions should be revisited when input systems, populations, operating conditions, or decision policies change.
Reporting standards are instruments, not certificates
TRIPOD+AI provides 27 main items, totaling 52 subitems, for transparent reporting of prediction-model studies. CONSORT-AI adds 14 items for clinical-trial reports involving AI, while DECIDE-AI provides 17 AI-specific items for early live clinical evaluation. The different scopes matter: model development and evaluation, randomized intervention testing, and early workflow evaluation are not interchangeable. A team should select guidance by study question and stage, sometimes using more than one framework.
A completed checklist does not establish low risk of bias or a positive benefit-risk balance. Reporting guidance makes appraisal possible by exposing data sources, participants, model handling, integration, errors, and limitations. Study quality still depends on design, execution, analysis, and relevance. The evidence dossier should therefore store the protocol and statistical analysis plan, registration, deviations, code and data access statement, checklist, results, risk-of-bias appraisal, and interpretation bounded to the design.
The live pilot is an experiment with stop rules
A pilot should test the smallest operational hypothesis that could justify the next stage. It needs a named population and site, trained users, baseline comparator, success and safety measures, monitoring, incident response, rollback, and an independent route for concerns. Silent deployment can first test data flow and performance without influencing decisions. Limited live use can then assess human factors and downstream effects. Scope should expand only after exit criteria are met.
Stop rules protect both participants and evidence quality. Examples include missed critical events above a threshold, unmanageable alert burden, performance degradation in a subgroup, unresolved security incidents, unauthorized data use, or dependence on manual rescue that invalidates the operating model. A stopped pilot is not necessarily a failed programme; it is a controlled finding. The decision log should state what was observed, whether the hypothesis survived, and which change would be necessary before retest.
Deployment is a maintained evidence state
Production is not the end of validation. Inputs drift, organizations change workflow, users adapt, dependencies update, and rare hazards accumulate. The operational dossier should bind each deployed version to approvals, test evidence, known limitations, configuration, training, monitoring thresholds, incidents, corrective actions, and retirement criteria. Periodic review asks whether the system still serves the intended population and purpose, whether benefits persist, and whether residual risk remains acceptable.
A research lab should publish maturity with calibrated language: concept, laboratory proof, relevant-environment prototype, prospective pilot, controlled outcome evaluation, or sustained operation. It should also publish the unresolved questions. This approach may look conservative beside a product launch, but it accelerates serious collaboration because partners can see what exists, what has been measured, and what experiment comes next. Research becomes deployment-ready when its claims remain traceable and falsifiable under real operating pressure.
Scope and limitations
NASA’s TRL framework was developed for aerospace and does not directly measure clinical, social, commercial, or regulatory readiness. The health-AI reporting guidelines cited apply to specific study designs and do not certify quality or safety. IMDRF guidance is a regulatory framework for software as a medical device, not every research technology. The proposed stage gates are a synthesis that requires domain-specific criteria, independent review, and applicable regulatory processes; they do not guarantee successful deployment.
References
Source review: 20 August 2026. Quantitative values retain their original definitions, periods, and boundaries.
- 01Technology Readiness Levels
National Aeronautics and Space Administration · 2023
www.nasa.gov ↗ - 02TRIPOD+AI statement
The BMJ · 2024
www.bmj.com ↗ - 03CONSORT-AI extension
Nature Medicine · 2020
www.nature.com ↗ - 04DECIDE-AI reporting guideline
Nature Medicine · 2022
www.nature.com ↗ - 05Software as a Medical Device: Clinical Evaluation
International Medical Device Regulators Forum · 2017
www.imdrf.org ↗ - 06Artificial Intelligence Risk Management Framework 1.0
US National Institute of Standards and Technology · 2023
nvlpubs.nist.gov ↗